Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014-2019.
Journal: Microbial drug resistance (Larchmont, N.Y.)
Published: May 30, 2023
Erratum for Karlowsky et al., "In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019".
Journal: Antimicrobial agents and chemotherapy
Published: May 08, 2023
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
Journal: International journal of antimicrobial agents
Published: March 02, 2023
Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check.
Journal: Frontiers in pharmacology
Published: January 24, 2023
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
Journal: Antimicrobial agents and chemotherapy
Published: September 26, 2022
In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
Journal: The Journal of antimicrobial chemotherapy
Published: September 12, 2022
Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
Journal: Microbial drug resistance (Larchmont, N.Y.)
Published: January 25, 2022
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
Journal: Expert review of anti-infective therapy
Published: December 23, 2021
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.
Journal: Infectious diseases and therapy
Published: December 08, 2021
In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019.
Journal: Antimicrobial agents and chemotherapy
Published: November 22, 2021
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 24, 2021
Erratum to: Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
Journal: The Journal of antimicrobial chemotherapy
Published: September 17, 2021
Last Updated: 09/26/2026